Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CHEK2 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

BRCA2 mutation + CHEK2 mutation (2)

CHEK2 mutation + ATM mutation + BRCA2 mutation (1)

BRCA2 mutation + CHEK2 mutation (2)

CHEK2 mutation + ATM mutation + BRCA2 mutation (1)

›

Related tests:

FoundationOne® CDx (110)

FoundationOne® CDx (110)

CHEK2 mutation	Prostate Cancer	CHEK2 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
CHEK2 mutation	Ovarian Cancer	CHEK2 mutation	Ovarian Cancer	olaparib Sensitive: B - Late Trials olaparib Sensitive : B	olaparib Sensitive: B - Late Trials olaparib Sensitive : B
CHEK2 mutation	HER2 Negative Breast Cancer	CHEK2 mutation	HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
CHEK2 mutation	Prostate Cancer	CHEK2 mutation	Prostate Cancer	rucaparib Sensitive: C2 – Inclusion Criteria rucaparib Sensitive : C2	rucaparib Sensitive: C2 – Inclusion Criteria rucaparib Sensitive : C2
CHEK2 mutation	HER2 Negative Breast Cancer	CHEK2 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3
CHEK2 mutation	Breast Cancer	CHEK2 mutation	Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
CHEK2 mutation	Pancreatic Ductal Adenocarcinoma	CHEK2 mutation	Pancreatic Ductal Adenocarcinoma	irinotecan Sensitive: C3 – Early Trials irinotecan Sensitive : C3	irinotecan Sensitive: C3 – Early Trials irinotecan Sensitive : C3
CHEK2 mutation	Tongue Carcinoma	CHEK2 mutation	Tongue Carcinoma	ABT-888 + M6620 Sensitive: C4 – Case Studies ABT-888 + M6620 Sensitive : C4	ABT-888 + M6620 Sensitive: C4 – Case Studies ABT-888 + M6620 Sensitive : C4
CHEK2 mutation	Testicular Cancer	CHEK2 mutation	Testicular Cancer	talazoparib Sensitive: C4 – Case Studies talazoparib Sensitive : C4	talazoparib Sensitive: C4 – Case Studies talazoparib Sensitive : C4
CHEK2 mutation	Prostate Cancer	CHEK2 mutation	Prostate Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4